Crosspoint Therapeutics

Developer of immunotherapies for cancer treatment

placeHwaseong, Gyeonggi Do, South Korea calendar_todayFounded 2022 language crosspointrx.com

Innovation

5 patent families — focus: Human necessities, Chemistry & metallurgy; filing pace active. Cited 14 times.

YearFilings
20255

Investor mix

6 investors on record; lead investors include Kudos Ventures, SU Investment.

Investor typeCountShare
Venture capital467%
Other / undisclosed233%
Coming soon